Most Popular in:
A handheld laser device designed to treat hair loss has been approved by the U.S. Food and Drug Administration.
The Florida company that makes the Hairmax Lasercomb said 26-week trials found that the device does increase the numbers of thick hairs on the scalp, the Associated Press reported.
Lexington International LLC said its device combines a low-level laser with a comb. When it's drawn through the hair, the laser affects the scalp in way that promotes hair growth.
According to the company, the Hairmax Lasercomb is the only FDA-approved drug-free product for home use in fighting hair loss. The device sells for $54 on the Web, the AP reported.
HealthDay News, February 16, 2007
Albuquerque, N.M. moved from 13th place last year to be named American's fittest city this year in the March issue of Men's Fitness magazine.
The other top 10 in the nonscientific survey of 50 cities are: Seattle; Colorado Springs; Minneapolis; Tucson, Ariz.; Denver; San Francisco; Baltimore; Portland, Ore.; and Honolulu, the Associated Press reported.
The magazine said this year's top 10 fattest cities are: Las Vegas, Nev.; San Antonio, Texas; Miami; Mesa. Ariz.; Los Angeles; Houston; Dallas; El Paso, Texas; Detroit; and San Jose, Calif.
The survey results are based on various lifestyle factors in each city, including the availability of bikes paths or gyms, commute times, fast food restaurants per capita, amount of television watching, along with federal statistics on obesity-related illnesses and injuries.
Magazine editor Neal Boulton told the AP that the list is published each year "to motivate folks to look at the simple things in their lives they can do to be healthy."
HealthDay News, February 9, 2007
By Michelle Kleist, RD
The U.S. Food and Drug Administration has ruled that the oral contraceptive YAZ can also be used by women to control moderate acne, the Associated Press reported..
The decision means that YAZ, made by Bayer Schering Pharma AG, is the first oral contraceptive to be approved by the FDA for three distinct uses, the drug maker said in a statement released Monday.
Along with birth control and acne treatment, YAZ is also approved in the United States to treat the physical and emotional symptoms of premenstrual dysphoric disorder, the AP reported.
HealthDay News, January 30, 2007
Regular acupressure treatment helps reduce agitated behavior in dementia patients, according to a small study by Taiwanese researchers.
Acupressure involves the application of pressure to certain points of the body.
This study of 20 dementia patients found that 15-minute acupressure sessions given twice a day, five days a week, led to noticeable improvements, including reduced wandering and less verbal and physical aggression.
During the sessions, each of five key pressure points was pressed for two minutes using three to five kilograms of pressure. The sessions lasted for four weeks. After the end of that treatment period, patient agitation levels started to increase again. That suggests that dementia patients require acupressure therapy on an ongoing basis, the researchers said.
The study is published in the February issue of the Journal of Clinical Nursing.
The findings have "important implications for the future care of dementia patients," study co-author Professor Li-Chan Lin, of the Institute of Clinical Nursing at National Yang-Ming University, said in a prepared statement. According to Lin, the study shows that acupressure "provides an effective option that, following training, can be carried out at home or in long-term care facilities."
"Agitated behavior in people with dementia is a major concern for caregivers. It can endanger patients and others, make it necessary for them to be moved from familiar surroundings and demoralize and psychologically distress caregivers," Lin noted.
"It is very important that we find interventions that enable us to provide more effective care for (dementia patients), both in their own home and in long-term care facilities," Lin said.
HealthDay News, January 26, 2007
IRIDEX Corporation completed its acquisition of the esthetics business of Laserscope.
By Rick Krupnick
Learn how offering LED therapy treatments can boost your spa’s revenue stream and increase your clientele.
By Jeff Falk
Aromatherapy—a concept that is thousands of years old—gets a boost from science and inspires the development of new products.
The U.S. Food and Drug Administration (FDA) has approved Radiesse, a cosmetic dermal filler, for the long-lasting correction of moderate to severe facial wrinkles and folds such as nasolabial folds.
Radiesse is composed of calcium hydroxylapatite microspheres in a water-based gel carrier. The product provides immediate improvement so a patient looks better the moment the product is injected. The calcium microsphere technology also enables the body to generate new collagen. Further, Radiesse provides physicians a high level of control, predictability and finesse for facial applications.
FDA approval of Radiesse for treatment of facial wrinkles and folds was based on the results of a clinical trial supporting Radiesse’s safety and effectiveness. In this study, conducted at four medical centers in the United States, 117 patients with nasolabial folds were treated with Radiesse on one side of the face and a control agent (Cosmoplast, a human collagen product) on the other. Results based on the ratings of three blinded evaluators showed that six months after treatment, Radiesse was more effective than the control on every comparative efficacy outcome (p<0.0001).
Key clinical findings include:
· 82 percent of nasolabial folds treated with Radiesse showed improvement after six months. This was significantly higher than the control, which showed improvement in only 27 percent of treated folds (p<0.0001).
· After six months, the fold treated with Radiesse was more improved in 79 percent of patients compared to the control-treated fold. The folds treated with the control rated more improved in only 5 percent of patients.
· The nasolabial folds treated with Radiesse required approximately half as much volume (1.22cc) than the folds treated with the control (2.35cc).
· Both products were safe and well tolerated, with no serious adverse events reported. In the 117 patients treated, Radiesse had zero granulomas and the same low rate of nodules as the control.
The U.S. Food and Drug Administration has approved a new treatment for moderate-to-severe frown lines, medically called nasolabial folds.
BioForm Medical issued a statement describing its Radiesse as a longer-lasting alternative to existing wrinkle fillers. The company said its calcium-based microsphere technology not only fills in facial folds and depressions, but also stimulates the body to produce collagen, the fibrous protein that gives the face its structure and fullness.
The drug was also newly approved to improve the appearance of people with AIDS-causing HIV who have significant facial fat loss (lipoatrophy), the San Mateo, Calif.-based company said.
Radiesse was first FDA approved in 2002 for use in facial reconstructive surgery.
HealthDay News, December 28, 2006